Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk
Yıl: 2022 Cilt: 52 Sayı: 4 Sayfa Aralığı: 1404 - 1407 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5448 İndeks Tarihi: 26-12-2022
Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk
Öz: -
Anahtar Kelime: Belge Türü: Makale Makale Türü: Editöre Mektup Erişim Türü: Erişime Açık
- 1. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S et al. The Transplantation Society International CMV Consensus Group. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation 2018; 102 (6): 900-931. doi: 10.1097/TP.0000000000002191
- 2. Fehr T, Cippà PE, Mueller NJ. Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy? Transplant International 2015; 28 (12): 1351-1356. doi: 10.1111/ tri.12629
- 3. Reddy SP, Handa A, Tan L, Devaney A, Hughes D et al. Low- dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients. Transplant International 2003; 16 (10): 726-729. doi: 10.1007/s00147-003-0612-4
- 4. Toussaint ND, Tan MB, Nicholls K, Walker RG, Cohney SJ. Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients. Nephrology (Carlton) 2011; 16 (1): 113-117. doi: 10.1111/j.1440-1797.2010.01379.x
- 5. Sund F, Tufveson G, Döhler B, Opelz G, Eriksson BM. Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience. Nephrology Dialysis Transplantation 2013; 28 (3): 758-765. doi: 10.1093/ndt/gfs531
- 6. Ljungman P, de La Camara R, Milpied N, Volin L, Russell CA et al. Valacyclovir International Bone Marrow Transplant Study Group. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002; 99 (8): 3050-3056. doi: 10.1182/blood.v99.8.3050
- 7. Kervan U, Kucuker SA, Kocabeyoglu SS, Unal EU, Ozatik MA et al. Low-Dose Valacyclovir for Cytomegalovirus Infection Prophylaxis After a Heart Transplant. Experimental Clinical and Transplantation 2016; 14 (5): 551-554. doi: 10.6002/ ect.2015.0109
- 8. Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H et al. VIPP Study Group. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 2012; 93 (1): 61-68. doi: 10.1097/TP.0b013e318238dab3
- 9. Werzowa J, Schwaiger B, Hecking M, Strassl R, Schmaldienst S et al. Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy. Clinical Transplantation 2015; 29 (12): 1230-1238. doi: 10.1111/ ctr.12657
- 10. Reischig T, Kacer M, Hes O, Machova J, Nemcova J et al. Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy. Am J Transplant 2019; 19: 2457–2467. doi: 10.1111/ajt.15507
- 11. Kacer M, Kielberger L, Bouda M, Reischig T. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective. Transplant Infectious Disease 2015; 17 (3): 334-341. doi: 10.1111/tid.12383
| APA | Velioglu A, alagöz s, Barutcu Atas D, Arikan H, Asicioglu E, Aksu B, Seyahi N, TUGLULAR Z (2022). Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk. , 1404 - 1407. 10.55730/1300-0144.5448 |
| Chicago | Velioglu Arzu,alagöz selma,Barutcu Atas Dilek,Arikan Hakki,Asicioglu Ebru,Aksu Burak,Seyahi Nurhan,TUGLULAR ZÜBEYDE SERHAN Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk. (2022): 1404 - 1407. 10.55730/1300-0144.5448 |
| MLA | Velioglu Arzu,alagöz selma,Barutcu Atas Dilek,Arikan Hakki,Asicioglu Ebru,Aksu Burak,Seyahi Nurhan,TUGLULAR ZÜBEYDE SERHAN Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk. , 2022, ss.1404 - 1407. 10.55730/1300-0144.5448 |
| AMA | Velioglu A,alagöz s,Barutcu Atas D,Arikan H,Asicioglu E,Aksu B,Seyahi N,TUGLULAR Z Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk. . 2022; 1404 - 1407. 10.55730/1300-0144.5448 |
| Vancouver | Velioglu A,alagöz s,Barutcu Atas D,Arikan H,Asicioglu E,Aksu B,Seyahi N,TUGLULAR Z Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk. . 2022; 1404 - 1407. 10.55730/1300-0144.5448 |
| IEEE | Velioglu A,alagöz s,Barutcu Atas D,Arikan H,Asicioglu E,Aksu B,Seyahi N,TUGLULAR Z "Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk." , ss.1404 - 1407, 2022. 10.55730/1300-0144.5448 |
| ISNAD | Velioglu, Arzu vd. "Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk". (2022), 1404-1407. https://doi.org/10.55730/1300-0144.5448 |
| APA | Velioglu A, alagöz s, Barutcu Atas D, Arikan H, Asicioglu E, Aksu B, Seyahi N, TUGLULAR Z (2022). Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk. Turkish Journal of Medical Sciences, 52(4), 1404 - 1407. 10.55730/1300-0144.5448 |
| Chicago | Velioglu Arzu,alagöz selma,Barutcu Atas Dilek,Arikan Hakki,Asicioglu Ebru,Aksu Burak,Seyahi Nurhan,TUGLULAR ZÜBEYDE SERHAN Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk. Turkish Journal of Medical Sciences 52, no.4 (2022): 1404 - 1407. 10.55730/1300-0144.5448 |
| MLA | Velioglu Arzu,alagöz selma,Barutcu Atas Dilek,Arikan Hakki,Asicioglu Ebru,Aksu Burak,Seyahi Nurhan,TUGLULAR ZÜBEYDE SERHAN Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk. Turkish Journal of Medical Sciences, vol.52, no.4, 2022, ss.1404 - 1407. 10.55730/1300-0144.5448 |
| AMA | Velioglu A,alagöz s,Barutcu Atas D,Arikan H,Asicioglu E,Aksu B,Seyahi N,TUGLULAR Z Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk. Turkish Journal of Medical Sciences. 2022; 52(4): 1404 - 1407. 10.55730/1300-0144.5448 |
| Vancouver | Velioglu A,alagöz s,Barutcu Atas D,Arikan H,Asicioglu E,Aksu B,Seyahi N,TUGLULAR Z Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk. Turkish Journal of Medical Sciences. 2022; 52(4): 1404 - 1407. 10.55730/1300-0144.5448 |
| IEEE | Velioglu A,alagöz s,Barutcu Atas D,Arikan H,Asicioglu E,Aksu B,Seyahi N,TUGLULAR Z "Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk." Turkish Journal of Medical Sciences, 52, ss.1404 - 1407, 2022. 10.55730/1300-0144.5448 |
| ISNAD | Velioglu, Arzu vd. "Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk". Turkish Journal of Medical Sciences 52/4 (2022), 1404-1407. https://doi.org/10.55730/1300-0144.5448 |
